Metabolic factors and non-alcoholic fatty liver disease as co-factors in other liver diseases

Digestive Diseases

Volumn 28, Issue 1, 2010, Pages 186-191

  Powell, Elizabeth E ^a,b   Jonsson, Julie R ^b   Clouston, Andrew D ^b,c  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c Envoi Pathology   (Australia)

Author keywords

Hepatitis C; Insulin resistance; Obesity

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; PEGINTERFERON; TUMOR NECROSIS FACTOR ALPHA;

ALCOHOL CONSUMPTION; ALCOHOL LIVER DISEASE; APOPTOSIS; CELL DEATH; CHRONIC LIVER DISEASE; CLINICAL TRIAL; COMORBIDITY; DIET THERAPY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; FATTY LIVER; HEMOCHROMATOSIS; HEPATITIS C; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER INJURY; LOW DRUG DOSE; LUNG FIBROSIS; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VIRUS INFECTION; WEIGHT REDUCTION;

APOPTOSIS; FATTY LIVER; HEPATITIS C, CHRONIC; HEPATOCYTES; HUMANS; INSULIN RESISTANCE; LIVER CIRRHOSIS; OBESITY;

EID: 77952580372     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000282084     Document Type: Review

References (19)

1. Ioannou GN, Weiss NS, Boyko EJ, Kahn SE, Lee SP: Contribution of metabolic factors to alanine aminotransferase activity in persons with other causes of liver disease. Gastroen- terology 2005;128:627-635.
2. Hickman IJ, Powell EE, Prins JB, Clouston AD, Ash S, Purdie DM, Jonsson JR: In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. J Hepatol 2003;39:1042-1048.
3. Jonsson JR, Barrie HD, O'Rourke P, Clouston AD, Powell EE: Obesity and steatosis influence serum and hepatic inflammatory markers in chronic hepatitis C. Hepatology 2008;48:80-87.
4. Clouston AD, Jonsson JR, Powell EE: Steatosis as a cofactor in other liver diseases: hepatitis C virus, alcohol, hemochromatosis, and others. Clin Liver Dis 2007;11:173-189.
5. Everhart JE, Lok AS, Kim HY, Morgan TR, Lindsay KL, Chung RT, Bonkovsky HL, Ghany MG, HALT-C Trial Group. Weight- related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology 2009;137:549-557.
6. Walsh MJ, Vanags DM, Clouston AD, Richardson MM, Purdie DM, Jonsson JR, Powell EE: Steatosis and liver cell apoptosis in chronic hepatitis C: a mechanism for increased liver injury. Hepatology 2004;39:1230-1238.
7. Clouston AD, Powell EE, Walsh MJ, Richardson MM, Demetris AJ, Jonsson JR: Fibrosis correlates with a ductular reaction in hepatitis C: roles of impaired replication, progenitor cells and steatosis. Hepatology 2005;41:809-818.
8. Chen CL, Yang HI, Yang WS, Liu CJ, Chen PJ, You SL, Wang LY, Sun CA, Lu SN, Chen DS, Chen CJ: Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 2008;135:111-121.
9. Bellentani S, Saccoccio G, Masutti F, Crocè LS, Brandi G, Sasso F, Cristanini G, Tiribelli C: Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000;132:112-117.
10. Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput JC: Excess weight risk factor for alcoholic liver disease. Hepatology 1997;25:108-111.
11. Raynard B, Balian A, Fallik D, Capron F, Bedossa P, Chaput JC, Naveau S: Risk factors of fibrosis in alcohol-induced liver disease. Hepatology 2002;35:635-638.
12. Fletcher LM, Dixon JL, Purdie DM, Powell LW, Crawford DH: Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis. Gastroenterology 2002;122:281-289.
13. Powell EE, Ali A, Clouston AD, Dixon JL, Lincoln DJ, Purdie DM, Fletcher LM, Powell LW, Jonsson JR: Steatosis is a cofactor in liver injury in hemochromatosis. Gastroenterology 2005;129:1937-1943.
14. Bondini S, Kallman J, Wheeler A, Prakash S, Gramlich T, Jondle DM, Younossi ZM: Impact of non-alcoholic fatty liver disease on chronic hepatitis B. Liver Int 2007;27:607-611. (Pubitemid 47097309)
15. Peng D, Han Y, Ding H, Wei L: Hepatic steatosis in chronic hepatitis B patients is associated with metabolic factors more than viral factors. J Gastroenterol Hepatol 2008;23:1082-1088.
16. Thomopoulos KC, Arvaniti V, Tsamantas AC, Dimitropoulou D, Gogos CA, Siagris D, Theocharis GJ, Labropoulou-Karatza C: Prevalence of liver steatosis in patients with chronic hepatitis B: a study of associated factors and of relationship with fibrosis. Eur J Gastroenterol Hepatol 2006;18:233-237.
17. Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases: Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-1374.
18. Hickman IJ, Clouston AD, Macdonald GA, Purdie DM, Prins JB, Ash S, Jonsson JR, Powell EE: Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002;51:89-94.
19. Hickman IJ, Jonsson JR, Prins JB, Ash S, Purdie DM, Clouston AD, Powell EE: Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004;53:413-419.